Evaluation of Urinary Human Telomerase Reverse Transcriptase mRNA and Scatter Factor Protein as Urine Markers for Diagnosis of Bladder Cancer
Date
2013
Journal Title
Journal ISSN
Volume Title
Type
Article
Publisher
Clin Lab
Series Info
Clin Lab;Volume: 59 Issue: 3-4 Pages: 317-23
Doi
Scientific Journal Rankings
Abstract
Background: Expression of the human telomerase reverse transcriptase (hTERT) gene, which codes for the catalytic subunit of telomerase is considered an important tumor marker used for bladder cancer detection being
found in the majority of cancer cells. Scatter Factor (SF) is a secretory protein produced by fibroblasts and
smooth muscles and induces scattering of the epithelial cells. The aim of the current study was to evaluate the potential usefulness of hTERT and SF measurement as urinary markers for bladder cancer diagnosis.
Methods: Voided urine specimens were collected from patients with histologically confirmed bladder urothelial
carcinoma (malignant group: n = 60), urological patients without urothelial carcinoma (benign group: n = 25), and
healthy volunteers (control group: n = 20). All cases underwent urine cytology, serological schistosomiasis antibody assay and detection of urinary hTERT mRNA using RT-PCR and SF using ELISA.
Results: Positivity rate of hTERT mRNA was markedly higher in malignant versus benign or control cases
(86.67%, 8%, and 0%, respectively, p-value < 0.001). Combining hTERT and cytology increased the sensitivity of
cytology to 95%. According to a cut-off value of urinary SF (≥ 410 ng/mg protein), 57 (95%) of the patients with
bladder carcinoma, 10 (40%) with benign lesions, and non of the control individuals were positive and the difference between the 3 groups was statistically significant (p < 0.001). The sensitivity of cytology was increased to
98.33% when combined with the SF assay. When associating the two urinary markers with different clinicopathological factors of the bladder cancer group, only SF exerted a significantly higher positivity rate at the invasive
stage (100%) than the superficial stage (88.46%) as well as in transitional cell carcinoma (100%) than squamous
cell carcinoma type (87.5%).
Conclusions: hTERT and SF can be considered potential useful markers for detection of bladder cancer.
Description
MSA Google Scholar
Keywords
University of hTERT, bladder cancer, RT PCR, scatter factor
Citation
1. Svatek RS, Sagalowsky AI, Lotan Y. Economic impact of screening for bladder cancer using bladder tumor markers: A decision analysis. Urol Oncol: Seminars and Original Investigations 2006; 24:338-43. 2. El Bolkainy MN. General pathology of cancer. National Cancer Institute, Cairo 2005. 3. Fernandez FA, Garcia EC, Fernandez RM. Influence of sex differences in biological aggressivity of bladder urothelial tumor at first diagnosis. Actas Urol Esp 1998;22:34-6. 4. Messing EM. Urothelial tumors of the urinary tract. In: Walsh PC, Retik AB Vaughan ED (eds). Campbell’s urology. 8th ed. Philadelphia: Saunders. 2002:2732. 5. Shariat SF, Karam JA, Lotan Y, et al. Follow-up of nonmuscle invasive transitional cell carcinoma of the bladder: how and how often? Curr Opin Urol 2008;18(5):504-7. 6. Planz B, Jochims E, Deix T, et al. The role of urinary cytology for detection of bladder cancer. Eur J Surg Oncol 2005;31(3):304-8. 7. Sanchini MA, Gunelli R, Nanni O, et al. Relevance of urine telomerase in the diagnosis of bladder cancer. JAMA 2005;294(16): 2052-6. 8. Muller M. Telomerase: its clinical relevance in the diagnosis of bladder cancer. Oncogene 2002;21:650-5. 9. Eissa S, Swellam M, Labib R, et al. Detection of telomerase in urine by 3 methods: evaluation of diagnostic accuracy for bladder cancer. J Urol 2007;178(3):1068-72. 10. Reisinger K, Kaufmann R, Gille J. Increased Sp1 phosphorylation as a mechanism of hepatocyte growth factor (HGF/SF)-induced vascular endothelial growth factor (VEGF/VPF) transcription. J Cell Sci 2003;116:225-38. 11. Zhang YW, Su YL, Volpert OV, Woude GF. Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VE GF and negative thrombospondin 1 regulation. PNAS 2003;100: 12718-23. 12. Matsumoto K, Nakamura T. Emerging multipotent aspects of hepatocyte growth factor. J Biochem 1996;119:591-600. 13. Sobin LH, Wittekind C. UICC TNM Classification of Malignant Tumors (5th ed.), Wiley Liss, New York 1997;187. 14. Histological Typing of Urinary Bladder Tumors, World Health Organization, Geneva, Switzerland 1973. 15. Eissa S, Swellam M, Labib R, et al. A panel of angiogenic factors for early bladder cancer detection: enzyme immumoassay and Western blot. J Urol 2009;181(3):1353-60. 16. Yoshida K, Sugino T, Tahara H. Telomerase in bladder carcinoma and its implication for noninvasive diagnosis by detection of exfoliated cancer cells in urine. Cancer 1997;79:362-9. 17. Eissa S, Kassim S, El-Ahmady O. Detection of bladder tumors: role of cytology, morphology-based assay, biochemical and molecular markers. Curr Opin Obstet Gynecol 2003;15(3):395-403. 18. Kim HR, Christensen R, Park NH, et al. Elevated expression of hTERT is associated with dysplastic cell transformation during human oral carcinogenesis in situ. Clin Cancer Res 2001;7(10): 3079-86. 19. Shervington A, Patel R. Differential hTERT mRNA processing between young and older glioma patients. FEBS Lett 2008;528 (12):1707-10. 20. Bradford MM. A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of proteindye binding. Anal Biochem 1976;72:248-54. 21. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993;39(4):561-77. 22. Fritsche HM, Burger M. Management of early-invasive highgrade transitional cell carcinoma of the bladder. Minerva Urol Nefrol 2008;60(4):265-71. 23. Eissa S, Kenawy G, Swellam M, et al. Comparison of cytokeratin 20 RNA and angiogenin in voided urine samples as diagnostic tools for bladder carcinoma. Clin Biochem 2004;37(9):803-10. 24. Rosen EM, Joseph A, Jin L, et al. Urinary and tissue levels of scatter factor in transitional cell carcinoma of bladder. J Urol 1997;157:72-8. 25. Wang P, Nishitani MA, Tanimoto S, et al. Bladder cancer cell invasion is enhanced by cross-talk with fibroblasts through hepatocyte growth factor. Urology 2007;69(4):780-4. 26. Kammula US, Kuntz EJ, Francone TD, et al. Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett 2007;248(2):219-28. 27. Jemal A, Murray T, Ward E, et al. Cancer Statistics. CA Cancer J Clin 2005;55:10-30. 28. Tsai YC, Nichols PW, Hiti AL, et al. Allelic losses of chromosomes 9, 11, and 17 in human bladder cancer. Cancer Res 1990; 50(1):44-7. 29. Gelmini S, Crisci A, Salvadori B, et al. Comparison of telomerase activity in bladder carcinoma and exfoliated cells collected in urine and bladder washings, using a quantitative assay. Clin Cancer Res 2000;6:2771–6. 30. de Kok JB, Ruers TJ, van Muijen GN, et al. Real-time quantification of human telomerase reverse transcriptase mRNA in tumors and healthy tissues. Clin Chem 2000;46:313-8. 31. Heine B, Hummel M, Müller M, et al. Non-radioactive measurement of telomerase activity in human bladder cancer, bladder washings, and in urine. J Pathol 1998;184:71-6. 32. Brems-Eskildsen AS, Zieger K, Toldbod H, et al. Prediction and diagnosis of bladder cancer recurrence based on urinary content of hTERT, SENP1, PPP1CA, and MCM5 transcript. BMC Cancer 2010;24(10):646. 33. Bowles L, Bialkowska-Hobrzanska H, Bukala B, et al. A prospective evaluation of the diagnostic and potential prognostic utility of urinary human telomerase reverse transcriptase mRNA in patients with bladder cancer. Can J Urol 2004;11:2438-44. 34 Moussa O, Abol-Enein H, Bissada NK et al. Evaluation of survivin reverse transcriptase-polymerase chain reaction for noninvasive detection of bladder cancer. J Urol 2006;175:2312-6.